| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations (NCT07738887) | The Lymphoma Academic Research Organisation | 2026-12-31 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT07739459) | The Lymphoma Academic Research Organisation | 2026-12-01 |
| Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas (NCT07514715) | The Lymphoma Academic Research Organisation | 2026-06-30 |
| Glofitamab in Real Life (NCT06994169) | The Lymphoma Academic Research Organisation | 2025-12-01 |
| Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (NCT06931652) | The Lymphoma Academic Research Organisation | 2025-09-22 |
| A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (NCT07018752) | The Lymphoma Academic Research Organisation | 2025-08-20 |
| Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma (NCT06558604) | The Lymphoma Academic Research Organisation | 2025-02-21 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse (NCT06271057) | The Lymphoma Academic Research Organisation | 2024-06-14 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (NCT06284122) | The Lymphoma Academic Research Organisation | 2024-06-07 |
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma (NCT06006117) | The Lymphoma Academic Research Organisation | 2023-09-05 |
| Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) (NCT05529524) | The Lymphoma Academic Research Organisation | 2022-11-07 |
| Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (NCT04802590) | The Lymphoma Academic Research Organisation | 2022-01-24 |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older (NCT04974216) | The Lymphoma Academic Research Organisation | 2021-12-20 |
| Study of Lacutamab in Peripheral T-cell Lymphoma (NCT04984837) | The Lymphoma Academic Research Organisation | 2021-10-05 |
| Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma (NCT04842877) | The Lymphoma Academic Research Organisation | 2021-06-11 |
| Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (NCT04703686) | The Lymphoma Academic Research Organisation | 2021-03-30 |
| Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (NCT04531046) | The Lymphoma Academic Research Organisation | 2021-03-10 |
| French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T) (NCT04328298) | The Lymphoma Academic Research Organisation | 2019-12-19 |
| Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma (NCT03892525) | The Lymphoma Academic Research Organisation | 2019-07-04 |
| Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (NCT03458260) | The Lymphoma Academic Research Organisation | 2018-12-26 |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (NCT03593018) | The Lymphoma Academic Research Organisation | 2018-11-09 |
| Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma (NCT03580408) | The Lymphoma Academic Research Organisation | 2018-08-31 |
| Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine (NCT03496779) | The Lymphoma Academic Research Organisation | 2018-04-10 |
| Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (NCT03276468) | The Lymphoma Academic Research Organisation | 2018-02-12 |